Senseonics makes Eversense, an implantable continuous glucose monitoring system for people with diabetes. SENS reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | TD Cowen | Reiterated | Buy | |
| Oct 7 | Barclays | Initiated | Hold | |
| Jul 15 | Mizuho | Maintained | Buy | |
| Oct 21 | Stifel | Reinstated | Hold |
Seasonality
How SENS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in SENS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SENS is in one of them and how their past SENS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SENS in an article yet. Here's the latest on the wider market.
About Senseonics Holdings
Senseonics is a medical technology company that makes Eversense, an implantable continuous glucose monitoring system for people with diabetes. A small sensor is placed under the skin and works with a rechargeable transmitter and a phone app to track glucose levels for up to a year. The company sells the system to people with diabetes and to the healthcare providers who treat them, and it works with distribution partners in some markets. It is based in Germantown, Maryland.
- Headquarters
- Germantown, MD
- Founded
- 1996
- Website
- senseonics.com ↗